PM1080 is an asymmetric 1+1 IgG-like bispecific antibody targeting EGFR x c-MET. After the fine tuning of the EGFR and c-MET binding domains, PM1080 preferentially interacts with EGFR/c-MET double positive cancers over EGFR single positive cells. This key feature allows PM1080 to potently suppress EGFR/c-MET expressing tumor progression either as a single agent or in combination with EGFR TKIs. Additionally, it significantly reduced conventional anti-EGFR-related toxicity resulting in a higher therapeutical window.